GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

RNXT · Jun 30, 2026

RenovoRx, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001193125-26-349190General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

7.81% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-315.40% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

115.40% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

42.13% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

84.27% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-368.43% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

132.01% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

62.71% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History7 statesHistory building

Dec 31, 20240/6 normalizedLevel 3 Mar 31, 20250/6 normalizedLevel 3 Jun 30, 20250/6 normalizedLevel 3 Sep 30, 20250/7 normalizedLevel 3 Dec 31, 20250/8 normalizedLevel 3 Mar 31, 20260/8 normalizedLevel 3 Jun 30, 20260/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 0.00%
Current: 7.81%
Delta: 7.81%

Cash Generation Increased

Previous: -658.79%
Current: -315.40%
Delta: 343.39%

Growth Decreased

Previous: 185.79%
Current: 115.40%
Delta: -70.38%

Inventory Pressure Decreased

Previous: 67.32%
Current: 42.13%
Delta: -25.18%

Margin Decreased

Previous: 85.08%
Current: 84.27%
Delta: -0.81%

Profitability Increased

Previous: -616.16%
Current: -368.43%
Delta: 247.74%

R And D Intensity Decreased

Previous: 218.12%
Current: 132.01%
Delta: -86.10%

Sbc Intensity Increased

Previous: 56.31%
Current: 62.71%
Delta: 6.40%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Compared To · Pharmaceutical Preparations peers →Transitioned To · RNXT Fundamental State →Transitioned To · RNXT CAPEX_INTENSITY_INCREASED →Transitioned To · RNXT CASH_GENERATION_INCREASED →Transitioned To · RNXT GROWTH_DECREASED →Transitioned To · RNXT INVENTORY_PRESSURE_DECREASED →Transitioned To · RNXT MARGIN_DECREASED →Transitioned To · RNXT PROFITABILITY_INCREASED →Transitioned To · RNXT R_AND_D_INTENSITY_DECREASED →Transitioned To · RNXT SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.